Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, which each address high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.
Company profile
Ticker
KYMR
Exchange
Website
CEO
Nello Mainolfi
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...
SEC CIK
Corporate docs
Subsidiaries
Kymera Securities Corporation ...
IRS number
812992166
KYMR stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Departure of Directors or Certain Officers
27 Feb 23
S-8
Registration of securities for employees
23 Feb 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
23 Feb 23
8-K
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution
10 Jan 23
8-K
Regulation FD Disclosure
14 Dec 22
8-K
Regulation FD Disclosure
14 Dec 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update
3 Nov 22
Latest ownership filings
4
Nello Mainolfi
3 Mar 23
4
Elaine Caughey
3 Mar 23
4
Jared Gollob
3 Mar 23
4
Bruce N. Jacobs
3 Mar 23
SC 13G/A
Atlas Venture Fund X, L.P.
14 Feb 23
SC 13G
BAKER BROS. ADVISORS LP
14 Feb 23
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 23
SC 13G
Avoro Capital Advisors LLC
14 Feb 23
SC 13G/A
Redmile Group, LLC
14 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 74.53 mm | 74.53 mm | 74.53 mm | 74.53 mm | 74.53 mm | 74.53 mm |
| Cash burn (monthly) | 29.08 mm | (no burn) | 12.88 mm | 13.44 mm | 13.18 mm | 12.76 mm |
| Cash used (since last report) | 88.38 mm | n/a | 39.13 mm | 40.84 mm | 40.05 mm | 38.77 mm |
| Cash remaining | -13.86 mm | n/a | 35.39 mm | 33.69 mm | 34.48 mm | 35.76 mm |
| Runway (months of cash) | -0.5 | n/a | 2.7 | 2.5 | 2.6 | 2.8 |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 123 |
| Opened positions | 20 |
| Closed positions | 21 |
| Increased positions | 45 |
| Reduced positions | 37 |
| 13F shares | Current |
|---|---|
| Total value | 1.30 tn |
| Total shares | 69.00 mm |
| Total puts | 291.20 k |
| Total calls | 1.12 mm |
| Total put/call ratio | 0.3 |
| Largest owners | Shares | Value |
|---|---|---|
| Atlas Venture Life Science Advisors | 5.98 mm | $149.38 bn |
| Atlas Venture Fund X | 5.07 mm | $0.00 |
| Biotechnology Value Fund L P | 4.69 mm | $149.37 mm |
| BVF | 4.69 mm | $117.13 bn |
| Wellington Management | 4.59 mm | $114.59 bn |
| T. Rowe Price | 4.38 mm | $110.28 bn |
| Avoro Capital Advisors | 3.85 mm | $96.10 bn |
| Vanguard | 3.66 mm | $91.36 bn |
| BLK Blackrock | 3.33 mm | $83.24 bn |
| VRTX Vertex Pharmaceuticals | 3.15 mm | $98.47 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 2 Mar 23 | Bruce N. Jacobs | Common Stock | Sell | Dispose S | No | Yes | 31.3973 | 314 | 9.86 k | 104,568 |
| 2 Mar 23 | Bruce N. Jacobs | Common Stock | Sell | Dispose S | No | Yes | 30.8774 | 1,056 | 32.61 k | 104,882 |
| 2 Mar 23 | Elaine Caughey | Common Stock | Sell | Dispose S | No | Yes | 31.3973 | 164 | 5.15 k | 18,986 |
| 2 Mar 23 | Elaine Caughey | Common Stock | Sell | Dispose S | No | Yes | 30.8774 | 550 | 16.98 k | 19,150 |
| 2 Mar 23 | Jared Gollob | Common Stock | Sell | Dispose S | No | Yes | 31.3973 | 297 | 9.32 k | 74,709 |
| 2 Mar 23 | Jared Gollob | Common Stock | Sell | Dispose S | No | Yes | 30.8774 | 1,001 | 30.91 k | 75,006 |
| 1 Mar 23 | Bruce N. Jacobs | Common Stock | Grant | Acquire A | No | No | 0 | 23,750 | 0.00 | 105,938 |
| 1 Mar 23 | Bruce N. Jacobs | Stock Option Common Stock | Grant | Acquire A | No | No | 32.07 | 142,500 | 4.57 mm | 142,500 |
| 1 Mar 23 | Nello Mainolfi | Stock Option Common Stock | Grant | Acquire A | No | No | 32.07 | 450,000 | 14.43 mm | 450,000 |
| 1 Mar 23 | Elaine Caughey | Common Stock | Grant | Acquire A | No | No | 0 | 10,557 | 0.00 | 19,700 |
News
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
11 Mar 23
Kymera Therapeutics's Return On Capital Employed Insights
27 Feb 23
Analyst Ratings for Kymera Therapeutics
24 Feb 23
Credit Suisse Maintains Neutral on Kymera Therapeutics, Raises Price Target to $39
24 Feb 23
HC Wainwright & Co. Reiterates Buy on Kymera Therapeutics, Maintains $85 Price Target
24 Feb 23